- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02699723
Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer
Oral Arsenic Trioxide and Itraconazole for the Treatment of Patients With Advanced Basal Cell Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To evaluate the response of arsenic trioxide/itraconazole in patients with refractory basal cell carcinoma.
SECONDARY OBJECTIVES:
I. To determine if this treatment is associated with a reduction in Gli messenger ribonucleic acid (mRNA) levels in tumor and/or normal skin biopsy samples, when compared to baseline levels.
OUTLINE:
Patients receive arsenic trioxide orally (PO) and itraconazole PO daily for 50 days, followed by maintenance therapy consisting of 2 weeks off treatment and then 2 weeks on treatment for up to 6 months in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 2 years.
Study Type
Phase
- Early Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Basal cell carcinoma (BCC)
- Patients ineligible for curative locoregional treatment and have either progressed on, did not tolerate, unwilling to try or ineligible for investigational smoothened antagonist such as Erivedge or Odomzo
- Life expectancy estimate > 3 months
- Performance status Eastern Cooperative Oncology Group (ECOG) 0 to 2
- Absolute neutrophil count >= 1,500/mcL
- Platelets >= 100,000/mcL
- Total bilirubin within normal institutional limits
- Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X institutional upper limit of normal
- Creatinine =< 1.9 mg/dL
- Corrected QT (QTC) by 12 lead electrocardiography (EKG) < 450 msecs
- Serum potassium, magnesium and calcium levels which fall within normal limits or levels outside the normal range determined not to be clinically significant by the principal investigator (PI)
- Serum prothrombin time, international normalized ratio (INR) and partial thromboplastin times which fall within normal limits or levels outside the normal range determined not to be clinically significant by the PI
- Ability to understand and the willingness to sign a written informed consent document
- Females and males of reproductive potential must use effective contraception during and after treatment for 6 months
Exclusion Criteria:
- Concurrent use of other investigational agents
- Cardiac arrhythmias
- Receiving potassium wasting diuretics or amphotericin must be noted to have theoretically increased arrhythmia risks with arsenic trioxide (potassium wasting diuretics or amphotericin are not excluded)
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, liver disease, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, recurrent seizure history or psychiatric illness/social situations that would limit compliance with treatment requirements
- Currently taking systemic medications that would affect BCC tumors (oral retinoids) or metabolism of itraconazole (anti convulsants and corticosteroids); itraconazole should not be taken with cisapride (Propulsid), dofetilide (Tikosyn), oral midazolam (Versed), nisoldipine (Sular), pimozide (Orap), quinidine (Quinaglute), triazolam (Halcion), or levomethadyl (Orlaam), lovastatin (Mevacor), simvastatin (Zocor), or an ergot medication such as dihydroergotamine (Migranal), ergometrine or ergonovine (Ergotrate Maleate), ergotamine (Ergomar), or methylergometrine or methylergonovine (Methergine)
- History or current evidence of malabsorption or liver disease that would impair the absorption of itraconazole
- History or current evidence of hyperthyroidism that would increase metabolism of itraconazole
- Immunosuppressed patients (cancer, autoimmune disease) or patients taking immunosuppressive drugs
- Pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (arsenic trioxide, itraconazole)
Patients receive arsenic trioxide PO and itraconazole PO daily for 50 days, followed by maintenance therapy consisting of 2 weeks off treatment and then 2 weeks on treatment for up to 6 months in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Given PO
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Gli levels
Time Frame: Baseline to up to 1 month
|
Nonparametric methods (Wilcoxon sign rank test) will be used given then the continuous outcome and small sample size.
|
Baseline to up to 1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor response using Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Time Frame: At 3 months
|
Proportion of subjects with complete response, partial response, stable disease, or disease progression by RECIST criteria.
|
At 3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jean Tang, Stanford Cancer Institute
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Basal Cell
- Carcinoma
- Carcinoma, Basal Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Arsenic Trioxide
- Itraconazole
Other Study ID Numbers
- IRB-35488
- NCI-2016-00180 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- SKIN0033 (Other Identifier: Stanford Cancer Institute)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Basal Cell Carcinoma
-
Anne ChangNational Cancer Institute (NCI); Merck Sharp & Dohme LLCCompletedSkin Basal Cell CarcinomaUnited States
-
Melanoma Institute AustraliaRecruitingSkin Cancer | Basal Cell Carcinoma | Invasive Carcinoma | Basal Cell Carcinoma of Skin, Site UnspecifiedAustralia
-
Kavita SarinNational Institutes of Health (NIH); Medivir; American Skin AssociationCompletedSkin Basal Cell CarcinomaUnited States
-
Jean Yuh TangNational Cancer Institute (NCI)CompletedSkin Basal Cell CarcinomaUnited States
-
Stanford UniversityCompletedSkin Cancer | Basal Cell Carcinoma (BCC)United States
-
Damae MedicalNot yet recruiting
-
Stanford UniversityNational Cancer Institute (NCI); University Hospitals Cleveland Medical CenterCompletedRecurrent Skin Cancer | Basal Cell Carcinoma of the SkinUnited States
-
AiViva BioPharma, Inc.CompletedNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
Sue YomGenentech, Inc.CompletedSkin Cancer | Locally Advanced Basal Cell Carcinoma | Cutaneous MalignancyUnited States
-
Elucid Labs Inc.UnknownMelanoma (Skin) | Squamous Cell Carcinoma of the Skin | Basal Cell Carcinoma of the SkinCanada
Clinical Trials on Laboratory Biomarker Analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
National Cancer Institute (NCI)Recruiting
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingLynch Syndrome | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingRecurrent Uterine Corpus Carcinoma | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
National Cancer Institute (NCI)Active, not recruitingMalignant NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingLung Cancer | Radiation Toxicity | Adult Brain TumorUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Askin TumorUnited States, Canada, Puerto Rico, Australia, New Zealand, Switzerland
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Osteosarcoma | Metastatic Osteosarcoma | Localized OsteosarcomaUnited States